{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-274053","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.335141+00:00","generated_at":"2026-06-08T07:12:37.024134+00:00","sec_items":["2.02","2.01","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cabaletta Bio Q3 2023 cash $164.4M; CABA-201 data expected H1 2024; IND clearances for SSc and gMG","bullets":["Cash, cash equivalents and short-term investments of $164.4M as of Sept 30, 2023, up from $106.5M at Dec 31, 2022.","R&D expenses $13.8M (vs $8.2M in Q3 2022); G&A expenses $4.9M (vs $3.6M).","Initial clinical data from CABA-201 Phase 1/2 trials in lupus and/or myositis expected in first half of 2024.","IND clearances received for CABA-201 in systemic sclerosis (SSc) and generalized myasthenia gravis (gMG).","WuXi ATU selected as GMP manufacturing partner; Oxford Biomedica as lentiviral vector supplier for CABA-201."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-274053","json":"https://secwatch.observer/filing/0001193125-23-274053.json","markdown":"https://secwatch.observer/filing/0001193125-23-274053.md","text":"https://secwatch.observer/filing/0001193125-23-274053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000119312523274053/0001193125-23-274053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000119312523274053/d581425d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:12:37.024134+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"67a1372df2f1a7598f0b22420fde068d0c81c17c","claim":"Cabaletta Bio, Inc. reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"On November 9, 2023, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000119312523274053/0001193125-23-274053-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}